This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
« Back
Page 1 of 574

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

06:40AM 10/31/14

Aegerion Problems Mount With Poor Quarter and Reduced Guidance

By Adam Feuerstein

The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals, the company he runs as CEO, is falling apart.

05:07PM 10/30/14

Aegerion Board Expresses Support for Embattled CEO Amid Drug Use Accusations

By Adam Feuerstein

Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board's support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex.

09:16AM 10/29/14

Arena Skimps on Data Disclosure From Weight-Loss Combo Study

By Adam Feuerstein

Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.

07:30AM 10/29/14

Divorce Suit Names CEOs Involved in Cocaine Use, Extramarital Sex Romps

By Adam Feuerstein

A dirty divorce for one of Wall Street's top bankers just got messier.

12:49PM 10/27/14

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

By Adam Feuerstein

FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.

11:02AM 10/27/14

Aegerion, Seattle Genetics CEOs Accused in Suit of Cocaine Use

By Adam Feuerstein

Both CEOs deny allegations in an ugly divorce case that they snorted cocaine with a Jefferies & Co. health care investment banker.

10:24AM 10/27/14

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08:28AM 10/24/14

Alcobra Applies Revisionist History to ADHD Drug Study Analysis

By Adam Feuerstein

Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 press release.

09:26AM 10/23/14

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

By Adam Feuerstein

But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.

11:52AM 10/22/14

« Back
Page 1 of 574

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,390.52 +195.10 1.13%
S&P 500 2,018.05 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs